Difficulties in correcting hyperphosphatemia in patients with chronic renal failure. A place of noncalcium-containing phosphate-binding drugs


Cite item

Full Text

Abstract

The review considers the current views of the mechanisms of hyperphosphatemia in patients with chronic renal failure. It shows indications for the use of different classes of phosphate-binding drugs to correct hyperphosphatemia.

References

  1. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. AJKD. 2000;35(4):117-131. doi: 10.1016/S0272-6386(00)70239-3
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl. 113):S1-S130.
  3. Cannata-Andfaz JB, Rodriguez-Garcia M, Carrillo-Lopez N, naves-Dfaz M, Dfaz-Lopez B. Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes. J Am Soc Nephrol. 2006;17:S267-S273. doi: 10.1681/ASN.2006080925
  4. Milovanova L, Milovanov Y, Plotnikova A. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III—IV (Systematic Rewiew and Meta-Analysis). Chronic Kidney Disease and renal Transplantation. Ed. by Manisha Sahay. INTECH. 2012;95-118.
  5. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрология и диализ. 2002;2(4):113-117.
  6. Razzaque MS. Phosphate toxicity: new insights into an old problem. Clin Scie. (Long). 2011;120(3):91-97. doi: 10.1042/CS20100377
  7. Block G, Klassen P, Lazarus J, Ofsthum N, Lortow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
  8. Young EW, Albert JM, Satavathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179-1187.
  9. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Российское диализное общество (май 2010 г.). Нефрология и диализ. 2011;13(1):33-51.
  10. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Нарушения фосфорно-кальциевого обмена при хронической болезни почек III—V стадией. Клиническая нефрология. 2011;1:58-68.
  11. Berndt Т, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda). 2009;24:17-25. doi: 10.1152/physiol.00034.2008
  12. Oliveira RB, Cancela ALE, Graciolli FG et al. Early Control of PTHand FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? Clin J Am Soc Nephrol. 2010;5(2):286-291. doi: 10.2215/CJN.05420709
  13. Милованова Л.Ю., Милованов Ю.С. Минеральные и костные нарушения при хронической болезни почек. Профилактика и лечение. Под ред. Козловской Л.В. М.: Инфра-М; 2014.
  14. Maltese G, Karalliadde J. The Putative Role of the Antiageing Protein Klotho in Cardiovascular and Renal Disease. Int J Hypertension. 2012;(2012). Article ID 757469. 5 pages http://dx.doi.org/10.1155/2012/757469
  15. Coladonato J. Control of Hyperphosphatemia among Patients with ESRD. J Am Soc Nephrol. 2005;16(11):suppl. 2:107-114. doi: 10.1681/ASN.2005060663
  16. Malluche HH, Mawad H. Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. 2002;17(7):1170-1175. PMID: 12105237 [PubMed — indexed for MEDLINE
  17. Tonelli MA, Alan CW, Garg AX, Holdaas H, Jardine AG, Jiang L, Kronenberg F, Parekh RS, Tetsuo S, Walker RJ. KGIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Am J Kidney Dis. 2007;49:S1-180.
  18. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Klin nephrol. 1998;50(6):381-386.
  19. Di Iorio B, Bellasi A, Russo D. on behalf of the INDEPENDENT Study Investigators Mortality in Kidney Disease Patients Treated with Phosphate Binders: A Randomized Study. Clin J Am Soc Nephrol. 2012;7(3):487-493. doi:10.2215CJN.03820411
  20. Ketteler M, Rix M, Fan S, Prithard N, Oestergaard O, Chasan-Taber S, Guggal A, Kalra PA. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1125-1130. doi: 10.2215/CJN.05161107
  21. Evenepoel P. Control of hyperphosphatemia beyond phosphate. Kidney Int. 2007;71:376-379.
  22. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445-454. doi: 10.1053/j.ajkd.2007.12.002
  23. Vasantha J, Soundararajan P, Vanitharani N, Kannan G, Thennarasu P, Neenu G, Reddy CU. Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. Indian J Nephrol. 2011;21(4):245-249. doi: 10.4103/0971-4065.83735

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies